Under construction – not a live service
Sign in
Taking peoplePhase 1

Comparing CT-P51 with Keytruda after surgery for melanoma

Compares blood levels of CT-P51 and Keytruda after melanoma surgery.

Key facts

Who runs it
Celltrion Inc.
Where
Meldola and Siena, ItalySee the 2 sitesAlso in 5 other countries, 14 sites
Registry title
A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma
Status
Recruiting
Phase
Phase 1
People taking part
83 people, planned
Started
2 Oct 2024
Expected to end
31 Mar 2027
Type of study
Interventional
Record updated
20 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose stage IIB, IIC or III melanoma has been completely removed by surgery. It compares three forms of pembrolizumab given after surgery.

Age
18 years or older
Sex
All sexes can join
Disease stage
Melanoma at stage IIB, IIC or III, completely removed by surgery

Where in Italy

Also in 5 other countries, 14 sites

  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.lMeldola, ItalyNo longer taking part
  • Azienda Ospedaliera Universitaria SeneseSiena, ItalyNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Comparing CT-P51 with Keytruda after surgery for melanomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
20 April 2026